Patents by Inventor Alan D. Martin

Alan D. Martin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220387600
    Abstract: Provided herein are certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to treat certain diseases, such as liver fibrosis, e.g., in the setting of NASH or ASH.
    Type: Application
    Filed: December 7, 2020
    Publication date: December 8, 2022
    Applicant: GENEVANT SCIENCES GMBH
    Inventors: James HEYES, Richard J. HOLLAND, Mark WOOD, Alan D. MARTIN, Christine ESAU, Margrit SCHWARZ, Xin YE, Alice Hoy Lam LI, Christopher Justin PASETKA, David CROWE, Steven TYLER
  • Publication number: 20220288214
    Abstract: Provided herein are certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. He conjugates are useful to treat certain diseases, such as acromegaly.
    Type: Application
    Filed: October 23, 2020
    Publication date: September 15, 2022
    Applicant: GENEVANT SCIENCES GMBH
    Inventors: Drew KONDRATOWICZ, James HEYES, Richard J. HOLLAND, Christine ESAU, Kevin MCCLINTOCK, Christopher Justin PASETKA, Mark WOOD, Alan D. MARTIN, Margrit SCHWARZ, David CROWE, Steven TYLER
  • Patent number: 11427823
    Abstract: The invention provides certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic double stranded siRNA to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: August 30, 2022
    Assignee: ARBUTUS BIOPHARMA CORPORATION
    Inventors: James Heyes, Richard J. Holland, Adam Judge, Amy C. H. Lee, Alan D. Martin, Nicholas Michael Snead, Emily P. Thi, Mark Wood, Xin Ye
  • Publication number: 20220168222
    Abstract: The invention provides lipid nanoparticles and formulations containing lipid nanoparticles.
    Type: Application
    Filed: April 24, 2020
    Publication date: June 2, 2022
    Applicant: GENEVANT SCIENCES GMBH
    Inventors: James HEYES, Adam JUDGE, Kieu Mong LAM, Alan D. MARTIN
  • Publication number: 20220001029
    Abstract: The invention provides certain specific lipid nanoparticles comprising: (a) one or more nucleic acid molecules; (b) cholesterol; (c) DSPC; (d) PEG-C-DMA; and (b) a cationic lipid of formula CL1 or CL2, and pharmaceutical compositions comprising the lipid nanoparticles. The lipid nanoparticles and pharmaceutical compositions are particularly useful for delivering a nucleic acid to a patient (e.g. a human) or to a cell.
    Type: Application
    Filed: November 8, 2019
    Publication date: January 6, 2022
    Applicant: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Kieu Mong LAM, Alan D. MARTIN, Petra SCHREINER
  • Publication number: 20200407724
    Abstract: The invention provides certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic double stranded siRNA to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).
    Type: Application
    Filed: April 10, 2018
    Publication date: December 31, 2020
    Applicant: ARBUTUS BIOPHARMA CORPORATION
    Inventors: James HEYES, Richard J. HOLLAND, Adam JUDGE, Amy C. H. LEE, Alan D. MARTIN, Nicholas Michael SNEAD, Emily P. THI, Mark WOOD, Xin YE
  • Publication number: 20200297870
    Abstract: The present invention provides compositions comprising mRNA molecules encapsulated within lipid particles. The lipid particles comprise a cationic lipid, a non-cationic lipid, and an mRNA molecule that is encapsulated within the lipid particle. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease. The invention also provides cationic lipids that are useful for preparing the compositions of the invention.
    Type: Application
    Filed: February 24, 2020
    Publication date: September 24, 2020
    Applicant: ARBUTUS BIOPHARMA CORPORATION
    Inventors: James HEYES, Lorne R. PALMER, Stephen P. REID, Edward D. YAWORSKI, Ian MACLACHLAN, Mark WOOD, Alan D. MARTIN
  • Publication number: 20190160176
    Abstract: The invention provides conjugates that comprise a targeting moiety, a nucleic acid, and optional linking groups as well as synthetic intermediates and synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic nucleic acids to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).
    Type: Application
    Filed: April 11, 2017
    Publication date: May 30, 2019
    Applicant: ARBUTUS BIOPHARMA CORPORATION
    Inventors: James HEYES, Richard J. HOLLAND, Alan D. MARTIN, Mark WOOD
  • Publication number: 20190106379
    Abstract: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.
    Type: Application
    Filed: August 20, 2018
    Publication date: April 11, 2019
    Applicant: ARBUTUS BIOPHARMA CORPORATION
    Inventors: James Heyes, Alan D. Martin, Mark Wood
  • Publication number: 20160256567
    Abstract: The present invention provides compositions comprising mRNA molecules encapsulated within lipid particles. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease. The invention also provided cationic lipids that are useful for preparing the compositions of the invention.
    Type: Application
    Filed: May 12, 2016
    Publication date: September 8, 2016
    Applicant: PROTIVA BIOTHERAPEUTICS, INC.
    Inventors: James HEYES, Lorne R. PALMER, Stephen P. REID, Edward D. YAWORSKI, Ian MACLACHLAN, Mark WOOD, Alan D. MARTIN
  • Publication number: 20160256568
    Abstract: The present invention provides compositions comprising mRNA molecules encapsulated within lipid particles. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease. The invention also provided cationic lipids that are useful for preparing the compositions of the invention.
    Type: Application
    Filed: May 12, 2016
    Publication date: September 8, 2016
    Applicant: PROTIVA BIOTHERAPEUTICS, INC.
    Inventors: James HEYES, Lorne R. PALMER, Stephen P. REID, Edward D. YAWORSKI, Ian MACLACHLAN, Mark WOOD, Alan D. MARTIN
  • Publication number: 20160151284
    Abstract: The present invention provides compositions comprising mRNA molecules encapsulated within lipid particles. The lipid particles comprise a cationic lipid, a non-cationic lipid, and an mRNA molecule that is encapsulated within the lipid particle. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease. The invention also provides cationic lipids that are useful for preparing the compositions of the invention.
    Type: Application
    Filed: July 22, 2014
    Publication date: June 2, 2016
    Applicant: PROTIVA BIOTHERAPEUTICS, INC.
    Inventors: James HEYES, Lorne R. PALMER, Stephen P. REID, Edward D. YAWORSKI, Ian MACLACHLAN, Mark WOOD, Alan D. MARTIN
  • Patent number: 6447309
    Abstract: An apparatus for suppressing power bus bouncing in a hot-swappable system has been developed. The apparatus includes a connection module with three interior pins for: the power return; the power supply; and the system ground. The system ground pin is shorter than the other two so that it makes contact with the power bus after the bouncing from the return and supply pins has subsided.
    Type: Grant
    Filed: December 12, 2000
    Date of Patent: September 10, 2002
    Assignee: Sun Microsystems, Inc.
    Inventors: Han Y. Ko, Robert C. Cyphers, Tomonori Hirai, Keith Y. Oka, Alan D. Martin
  • Publication number: 20020072259
    Abstract: An apparatus for suppressing power bus bouncing in a hot-swappable system has been developed. The apparatus includes a connection module with three interior pins for: the power return; the power supply; and the system ground. The system ground pin is shorter than the other two so that it makes contact with the power bus after the bouncing from the return and supply pins has subsided.
    Type: Application
    Filed: December 12, 2000
    Publication date: June 13, 2002
    Inventors: Han Y. Ko, Robert C. Cyphers, Tomonori Hirai, Keith Y. Oka, Alan D. Martin
  • Patent number: 5564108
    Abstract: This apparatus makes use of the existing data collection probe connector on the instrumentation as the port through which the software updates are loaded into the programmable memory devices that are used to store the operational software of the instrumentation. Circuitry is provided in the instrumentation to automatically differentiate between software update data being loaded into the instrumentation and the normal monitoring data that is received from the probe. This is accomplished by the use of probe defining circuitry that is able to differentiate between the standard probe used for data collection purposes and the software update probe that is provided to download software into the programmable memory devices.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: October 8, 1996
    Assignee: Ohmeda Inc.
    Inventors: Scott W. Hunsaker, Stephan Kulik, III, Alan D. Martin, Craig A. Totel
  • Patent number: 4846183
    Abstract: A pulse oximeter or plethysmographic device utilizes light varying in intensity at a predetermined carrier frequency. A passive resonant circuit having a resonant frequency substantially equal to the carrier frequency is connected between the photodetector and the first amplifier. The resonant circuit serves to suppress spurious DC and low frequency components such as those due to ambient light and ambient light flicker and also to suppress high frequency interference. Because ambient light signals are suppressed, there is no need for dark current correction or restoration. Suppression of ambient light and other interference upstream of the front end amplifier avoids saturation of the amplifier and permits use of a front end amplifier having high gain.
    Type: Grant
    Filed: December 2, 1987
    Date of Patent: July 11, 1989
    Assignee: The BOC Group, Inc.
    Inventor: Alan D. Martin
  • Patent number: 4781195
    Abstract: In photoelectric apparatus such as a pulse oximeter for monitoring a parameter of the blood in a living organism, a dark current correction signal is applied to the input at the preamplifier. The correction signal is substantially equal in magnitude but opposite in sense to the photodetector output during dark intervals when the illumination means of the apparatus is disabled. Because dark current correction is accomplished at the input of the preamplifier, the preamplifier has substantially increased resistance to overloading caused by ambient light and hence may have higher gain.
    Type: Grant
    Filed: December 2, 1987
    Date of Patent: November 1, 1988
    Assignee: The BOC Group, Inc.
    Inventor: Alan D. Martin